BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
BMY is focused on developing drugs with presence in oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. BMY depends on label expansion of approved drugs and approval of new drugs to stabilize its revenue base as its legacy drugs (Revlimid, Pomalyst, Sprycel and Abraxane) face generic competition.
The company recently announced that the late-stage study on Sotyktu (deucravacitinib), an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in adults with active psoriatic arthritis met its primary endpoint.
The drug is already approved in numerous countries around the world for the treatment of adults with moderate-to-severe plaque psoriasis. BMY is also evaluating Sotyktu in late-stage studies for the treatment of Sjögren's syndrome and systemic lupus erythematosus.
However, Sotyktu faces stiff competition from Amgen 's AMGN Otezla in the psoriasis space. Notably, Amgen acquired global commercial rights to Otezla from erstwhile Celgene (now part of Bristol-Myers). Amgen is also evaluating Otezla in additional indications.
Last month, the European Commission ('EC') approved the subcutaneous formulation of Opdivo (nivolumab) across multiple solid tumor indications. The EC had earlier approved a perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by adjuvant Opdivo for resectable, high-risk non-small cell lung cancer with PD-L1 Expression ≥1%.
Opdivo is a key drug in BMY's Growth Portfolio. The FDA had earlier approved Opdivo plus Yervoy as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma.
While the label expansion of Opdivo is positive, the immuno-oncology space is dominated by pharma giant Merck 's MRK blockbuster drug Keytruda (pembrolizumab).
Keytruda is approved for several types of cancer and alone accounts for around 50% of its MRK's pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
BMY's Price Performance, Valuation and Estimates
Shares of Bristol Myers have lost 8.4% year to date against the industry 's growth of 1.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY's shares currently trade at 7.80x forward earnings, lower than its mean of 8.55x and the large-cap pharma industry's 15.71X.
The Zacks Consensus Estimate for 2025 earnings per share has moved up to $6.85 from $6.78 in the past 60 days, while that for 2026 has moved south.
BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Citi Pounds the Table on Nvidia Stock, Citing Big Opportunity in Europe
Nvidia (NASDAQ:NVDA) has faced investor concerns over its positioning in China, with worries mounting about export restrictions on AI chips to the Eastern superpower. In the meantime, however, the semiconductor giant has been securing deals in another key region. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter On Wednesday, CEO Jensen Huang took the stage in Paris at Nvidia's GTC event, delivering a keynote where he delivered a keynote unveiling several important partnerships across Europe. He revealed collaborations with multiple European governments, including France, Germany, Italy, Spain, and the UK, to build out sovereign AI infrastructure. Among the headline initiatives is Europe's first industrial AI cloud in Germany, designed specifically for the region's manufacturing sector. The facility, powered by NVIDIA DGX B200 systems and RTX PRO Servers, will leverage 10,000 NVIDIA Blackwell GPUs to establish a cutting-edge AI factory. In France, a major GPU deployment in partnership with Mistral AI will see 18,000 Blackwell GPUs installed near Paris. Meanwhile, in the U.K., NVIDIA Cloud Partners revealed the first stage of their AI infrastructure rollout, involving the deployment of 14,000 Blackwell GPUs to support new enterprise-focused data centers across the country. Collectively, the EU is investing €30 billion in AI factories, which includes plans for five gigafactories, each equipped with 100,000 AI accelerators. Overall, Nvidia estimates that over the next several years, roughly $1.5 trillion will be invested in building AI sovereign factories. While Europe's pace has lagged behind the U.S. due to a less developed tech ecosystem, Citi analyst Atif Malik, who's ranked among the top 15 on Wall Street, argues that the region's distinct strengths and long-term commitments shouldn't be overlooked. The 5-star analyst counts three main takeaways from these developments. First, Europe looks set to keep importing advanced AI accelerators without major disruption, easing fears that escalating tariffs could spill into the AI space. Second, while the EU's plan to deploy over 750,000 AI accelerators is ambitious, Malik notes it still lags behind the scale seen in the Middle East, where the UAE alone is eyeing 500,000 units annually. Given the region's stronger access to capital and energy, he sees its lead in AI infrastructure investment as a natural outcome. Lastly, Malik views the surge in sovereign AI projects as a clear win for Nvidia, since many of these systems are likely to rely heavily on merchant GPUs. What's the takeaway for investors? Malik has a Buy rating on NVDA shares, with a $180 price target that suggests the stock could surge another 26% in the months ahead. (To watch Malik's track record, click here) The Citi analyst is far from alone. Of the 40 analysts weighing in, 35 are in the bull camp, joined by 4 Holds and just 1 lone Sell. All told, it comes down to a resounding Strong Buy consensus rating. The average price target of $172.36 implies shares could rise by ~21% over the next year. (See NVDA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Globe and Mail
12 hours ago
- Globe and Mail
1 Magnificent High-Yield Stock Down 55% to Buy and Hold Forever
Headline-grabbing news events often push investors into emotional investing decisions. That's exactly what is taking place today with regard to tariffs. The investor reaction to tariffs has pushed industry-leading industrial real estate investment trust (REIT) Prologis (NYSE: PLD) down 35% from its 2022 highs and led to an attractive yield of 3.7%. You can do even better, collecting a 4.7% yield, with this well-positioned industrial REIT that is down 55%. Here's what you need to know. Why are investors downbeat on Prologis? Prologis is an industrial REIT giant, with operations across North America, South America, Europe, and Asia. It owns 5,900 buildings containing 1.3 billion square feet of space. But the key part of the story is where its buildings are located. Prologis has assets in just about every major transportation hub in the world, serving 6,500 customers looking to import and export goods. This is a huge business strength, but right now it is seen as a huge negative. That's because U.S. tariffs have upended international trade norms. That's pushed Prologis' stock price down and its yield up. This is definitely a short-term disruption, but it seems unlikely to become a permanent negative. The world is so interconnected today that the more likely outcome is that trade patterns shift and Prologis' diverse portfolio of assets is still highly valuable. Prologis is, indeed, an attractive dividend investment opportunity today. And yet there's an even more interesting story to be told with Rexford Industrial Realty (NYSE: REXR). Highly focused Rexford is deeply out of favor Like Prologis, Rexford owns industrial assets that are vital to international trade. The most important difference between the two REITs is that Rexford is focused on just one single market, Southern California. It owns 424 properties with 51 million square feet of space in them. The key here is that Southern California is the major gateway for Asian goods entering the U.S. market (and vice versa). That, of course, is the problem, given the high-profile tariff fight between the United States and China. The near-term uncertainty has led investors to abandon Rexford. But, like Prologis, it seems more likely that international trade will adjust to a new normal than stop entirely. That alone makes Rexford's lofty 4.7% dividend yield attractive, but there's more. Southern California is a supply-constrained market. That gives Rexford a strong negotiating position when signing leases. Rexford is also a skilled redeveloper, frequently buying older assets and upgrading them so that they are more modern and desirable. That also helps its ability to raise rents. To be fair, the highly concentrated nature of Rexford's business does make it riskier than more diversified Prologis. But unless you believe international trade is going to stop, Rexford should come out the other side of the current uncertainty in a strong position. The opportunity to buy Rexford Industrial is in the here and now Oftentimes the best opportunities to buy a well-run company arise when Wall Street is overly pessimistic. The key is to figure out if the worry is about something that will linger or something that is likely to be temporary. The upheaval in international trade seems like a temporary issue, given how interconnected the world is today. For more conservative investors that could make Prologis an attractive option, while more aggressive investors will probably prefer higher-yielding Rexford industrial. And if you do buy one of these high-yield industrial REITs you'll probably end up owning it for the long term. Should you invest $1,000 in Prologis right now? Before you buy stock in Prologis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Prologis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $655,255!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $888,780!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
CTV News
19 hours ago
- CTV News
Rockey's Harley Davidson closing down by end of the month
Long-time London dealership, Rocky's Harley Davidson, is closing its doors. The owner said it's because of mounting economic pressures. The dealership's management posted on social media that the retail landscape is declining and there's ongoing instability in the industry. Currently, the store is operating on an appointment-only basis until it closes permanently on June 30.
